These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27687743)

  • 1. Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence.
    Nunes EV; Lee JD; Sisti D; Segal A; Caplan A; Fishman M; Bailey G; Brigham G; Novo P; Farkas S; Rotrosen J
    Contemp Clin Trials; 2016 Nov; 51():34-43. PubMed ID: 27687743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.
    Lee JD; Nunes EV; Mpa PN; Bailey GL; Brigham GS; Cohen AJ; Fishman M; Ling W; Lindblad R; Shmueli-Blumberg D; Stablein D; May J; Salazar D; Liu D; Rotrosen J
    Contemp Clin Trials; 2016 Sep; 50():253-64. PubMed ID: 27521809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An alternative analysis of illicit opioid use during treatment in a randomized trial of extended-release naltrexone versus buprenorphine-naloxone: A per-protocol and completers analysis.
    Mitchell MM; Schwartz RP; Choo TH; Pavlicova M; O'Grady KE; Gryczynski J; Stitzer ML; Nunes EV; Rotrosen J
    Drug Alcohol Depend; 2021 Feb; 219():108422. PubMed ID: 33352487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
    Lee JD; Nunes EV; Novo P; Bachrach K; Bailey GL; Bhatt S; Farkas S; Fishman M; Gauthier P; Hodgkins CC; King J; Lindblad R; Liu D; Matthews AG; May J; Peavy KM; Ross S; Salazar D; Schkolnik P; Shmueli-Blumberg D; Stablein D; Subramaniam G; Rotrosen J
    Lancet; 2018 Jan; 391(10118):309-318. PubMed ID: 29150198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.
    Roache JD; Pavlicova M; Campbell A; Choo TH; Peavy M; Kermack AS; Nunes EV; Rotrosen J
    Alcohol Clin Exp Res; 2021 Dec; 45(12):2569-2578. PubMed ID: 34698397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians.
    Randesi M; Rotrosen J; Nunes EV; Lee JD; Novo P; Levran O; Ott J; Pavlicova M; Scodes J; Kreek MJ
    Am J Drug Alcohol Abuse; 2020 Nov; 46(6):761-768. PubMed ID: 32851876
    [No Abstract]   [Full Text] [Related]  

  • 7. Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adults.
    Haeny AM; Montgomery L; Burlew AK; Campbell ANC; Scodes J; Pavlicova M; Rotrosen J; Nunes E
    Addict Behav; 2020 Nov; 110():106514. PubMed ID: 32619868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline- and treatment-associated pain in the X:BOT comparative effectiveness study of extended-release naltrexone versus buprenorphine-naloxone for OUD.
    Wang AL; Shulman M; Choo TH; Pavlicova M; Langleben DD; Nunes EV; Rotrosen J
    Addict Biol; 2022 Mar; 27(2):e13112. PubMed ID: 34877769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment.
    Nunes EV; Scodes JM; Pavlicova M; Lee JD; Novo P; Campbell ANC; Rotrosen J
    Am J Psychiatry; 2021 Jul; 178(7):660-671. PubMed ID: 34170188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A Retrospective Chart Review.
    Shirk SD; Ameral V; Kraus SW; Houchins J; Kelly M; Pugh K; Reilly E; Desai N
    J Dual Diagn; 2021; 17(3):207-215. PubMed ID: 34176448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis.
    Murphy SM; Jeng PJ; McCollister KE; Leff JA; Jalali A; Shulman M; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
    Addiction; 2021 Dec; 116(12):3444-3453. PubMed ID: 33950535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
    Solli KK; Latif ZE; Opheim A; Krajci P; Sharma-Haase K; Benth JŠ; Tanum L; Kunoe N
    Addiction; 2018 Oct; 113(10):1840-1849. PubMed ID: 29806872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.
    Ling W; Hillhouse MP; Saxon AJ; Mooney LJ; Thomas CM; Ang A; Matthews AG; Hasson A; Annon J; Sparenborg S; Liu DS; McCormack J; Church S; Swafford W; Drexler K; Schuman C; Ross S; Wiest K; Korthuis PT; Lawson W; Brigham GS; Knox PC; Dawes M; Rotrosen J
    Addiction; 2016 Aug; 111(8):1416-27. PubMed ID: 26948856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX).
    Kunøe N; Opheim A; Solli KK; Gaulen Z; Sharma-Haase K; Latif ZE; Tanum L
    BMC Pharmacol Toxicol; 2016 Apr; 17(1):18. PubMed ID: 27121539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does XR injectable naltrexone prevent relapse as effectively as daily sublingual buprenorphine-naloxone?
    Roe M; Wilson CG; Fusco CW; Hulkower S; Stigleman S
    J Fam Pract; 2020 Dec; 69(10):E14-E15. PubMed ID: 33348352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting the X:BOT Naltrexone Clinical Trial Using a Comprehensive Survival Analysis.
    Ajazi EM; Dasgupta N; Marshall SW; Monaco J; Howard AG; Preisser JS; Schwartz TA
    J Addict Med; 2022 Jul-Aug 01; 16(4):440-446. PubMed ID: 35960214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients' perspectives on initiating treatment with extended-release naltrexone (XR-NTX).
    Gauthier P; Greco P; Meyers-Ohki S; Desai A; Rotrosen J
    J Subst Abuse Treat; 2021 Mar; 122():108183. PubMed ID: 33162260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.
    Di Paola A; Lincoln T; Skiest DJ; Desabrais M; Altice FL; Springer SA
    Contemp Clin Trials; 2014 Nov; 39(2):256-68. PubMed ID: 25240704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.
    Mooney LJ; Nielsen S; Saxon A; Hillhouse M; Thomas C; Hasson A; Stablein D; McCormack J; Lindblad R; Ling W
    Contemp Clin Trials; 2013 Mar; 34(2):196-204. PubMed ID: 23159524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone.
    Tsui JI; Campbell ANC; Pavlicova M; Choo TH; Lee JD; Cook RR; Shulman M; Nunes EV; Rotrosen J
    Drug Alcohol Depend; 2022 Jul; 236():109469. PubMed ID: 35605529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.